MEME MALİGN NEOPLAZMLARINDA TRU-CUT VE EKSİZYONEL BİYOPSİ MATERYALLERİNİN C-erbB2 EKSPRESYONLARININ FARKLI İKİ MERKEZDE DEĞERLENDİRİLEREK KARŞILAŞTIRILMASI; 50 OLGUNUN RETROSPEKTİF ANALİZİ

Abstract

Comparison of C-erbB2 Expressions of Tru-Cut and Excisional Biopsy Materials in Breast Malignant Neoplasms in Two Different Centers; Retrospective Analysis of 50 Cases Aim: The most common type of cancer in women is breast carcinoma. There is an improvement in prognosis with the developments in early diagnosis possibilities parallel to the developments seen in laboratory methods. One of the important factors in determining the prognosis and response to treatment is the Human Epidermal Growth Factor Receptor 2 (HER2, cerbB2) gene located on the long arm of Chromosome 17. One of the most frequently used methods in the evaluation of HER-2 gene in breast carcinoma in many medical pathology laboratories is immunohistochemical (IHC) methods. In the IHC method, scoring is made according to the staining percentage of invasive carcinoma cells and the quality of staining (weak-medium-strong / incomplete-complete membranous). In this study, we aimed to reveal the possible differences and their reasons by comparing the IHC evaluation scores of both centers. Methods: Fifty patients who were diagnosed with breast carcinoma in the last 5 years in our Medical Pathology laboratory, IHC studies were conducted, IHC studies were repeated in Erzurum Atatürk University Medical Pathology Laboratory for various reasons, and both tru-cut biopsy and excisional biopsies were evaluated in both centers. Pathology reports of 50 cases were analyzed retrospectively. Results: When the evaluations made in both centers were compared, 30 (60%) of tru-cut biopsy materials and 31 (62%) of excisional biopsy materials had the same score. Conclusion : Although there are similarities between the two centers in the evaluation results, substantial differences were also detected.